Loading
A third immunotherapy confirmed the benefit in dMMR disease and hinted that adding olaparib helps the mismatch-repair-proficient majority.
Durvalumab alone: PFS HR 0.71 overall and 0.42 in dMMR. Durvalumab + olaparib: PFS HR 0.55 overall and 0.57 in pMMR (JCO 2023). FDA approved durvalumab with chemotherapy for dMMR disease in June 2024; the EU approved both the durvalumab and durvalumab + olaparib regimens (pMMR for the latter) in 2024.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
718 enrolled.
Numbers not yet public.
SourceShares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Chemotherapy + PD-1/PD-L1 blockade, first-line advanced endometrial cancer, Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR).
Shares Advanced or recurrent endometrial cancer, Durvalumab, Endometrial cancer, AstraZeneca.
Shares PARP, Olaparib, Durvalumab, PD-L1.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares Mismatch-repair-deficient endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer, Carboplatin.
Shares DUO-E: durvalumab with carboplatin-paclitaxel and maintenance durvalumab with or without olaparib in advanced endometrial cancer, Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Paclitaxel / nab-paclitaxel, AstraZeneca.